2025
The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial
Feng S, Zhang Y, Khanam F, Voysey M, Pitzer V, Qadri F, Clemens J, Pollard A, Liu X. The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial. The Lancet Global Health 2025, 13: e1122-e1131. PMID: 40252689, PMCID: PMC12095117, DOI: 10.1016/s2214-109x(25)00056-7.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineCluster randomised controlled trialJapanese encephalitis vaccineAge-eligible childrenCohort designTest-negative controlsStudy designTyphoid feverVaccine effectivenessHealth care seeking behaviorNon-vaccineesIncreased riskBlood culture-confirmed typhoid feverSalmonella enterica serotype TyphiCase-control study designNon-typhoidal infectionsVaccine protectionBlood culture specimensExperimental study designMiddle-income countriesObservational study designPublic health challengeChildren aged 9 monthsIncreased risk of typhoid feverRisk of typhoid fever
2024
5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial
Qadri F, Khanam F, Zhang Y, Biswas P, Voysey M, Mujadidi Y, Kelly S, Bhuiyan A, Rajib N, Hossen I, Rahman N, Islam S, Pitzer V, Kim Y, Clemens J, Pollard A, Liu X. 5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial. The Lancet 2024, 404: 1419-1429. PMID: 39396349, DOI: 10.1016/s0140-6736(24)01494-6.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineJapanese encephalitis vaccineVaccine effectivenessRandomised controlled trialsConjugate vaccineFollow-upTyphoid feverControlled TrialsVaccine protectionChildren aged 9 monthsIncreased risk of typhoid feverAnti-Vi IgGRisk of typhoid feverVaccine efficacy dataTest-negative designAged 9 monthsUnvaccinated individualsHigh-burden countriesIncidence rate ratiosAnalyses of vaccine effectivenessSingle-doseSingle doseDecay of antibodiesSubgroup analysisBooster dose
2023
Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023)
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection (Small Methods 10/2023). Small Methods 2023, 7 DOI: 10.1002/smtd.202370057.Peer-Reviewed Original ResearchMicrofluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection
Kim D, Biancon G, Bai Z, VanOudenhove J, Liu Y, Kothari S, Gowda L, Kwan J, Buitrago‐Pocasangre N, Lele N, Asashima H, Racke M, Wilson J, Givens T, Tomayko M, Schulz W, Longbrake E, Hafler D, Halene S, Fan R. Microfluidic Immuno‐Serolomic Assay Reveals Systems Level Association with COVID‐19 Pathology and Vaccine Protection. Small Methods 2023, 7: e2300594. PMID: 37312418, PMCID: PMC10592458, DOI: 10.1002/smtd.202300594.Peer-Reviewed Original ResearchConceptsB cell depletion therapyAcute COVID infectionAnti-spike IgGHigh-risk patientsCoronavirus disease-19COVID-19 pathologyDepletion therapyVaccine protectionAntibody responseCOVID infectionHematologic malignanciesImmune protectionDisease-19Healthy donorsMultiple time pointsSerology assaysBlood samplesSoluble markersB cellsImmunization strategiesPatientsFunctional deficiencySerological analysisTime pointsClonotype diversityBiological rhythms in COVID-19 vaccine effectiveness in an observational cohort study of 1.5 million patients
Hazan G, Duek O, Alapi H, Mok H, Ganninger A, Ostendorf E, Gierasch C, Chodick G, Greenberg D, Haspel J. Biological rhythms in COVID-19 vaccine effectiveness in an observational cohort study of 1.5 million patients. Journal Of Clinical Investigation 2023, 133: e167339. PMID: 37053011, PMCID: PMC10231992, DOI: 10.1172/jci167339.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccinationBreakthrough infectionsVaccine effectivenessVaccination timingCOVID-19 breakthrough infectionsCOVID-19-related hospitalizationCOVID-19 vaccine effectivenessBasic immune processesSecond booster doseObservational cohort studyEmergency department visitsMass vaccination programBooster doseVaccination timeBooster dosesCohort studyOlder patientsPatient ageDepartment visitsVaccine protectionCox regressionIsraeli cohortClinical endpointsVaccination programImmunization time
2017
Panel 6: Vaccines
Pettigrew MM, Alderson MR, Bakaletz LO, Barenkamp SJ, Hakansson AP, Mason KM, Nokso‐Koivisto J, Patel J, Pelton SI, Murphy TF. Panel 6: Vaccines. Otolaryngology 2017, 156: s76-s87. PMID: 28372533, PMCID: PMC5505493, DOI: 10.1177/0194599816632178.Peer-Reviewed Original ResearchConceptsPneumococcal otitis mediaOtitis mediaVaccine antigensVaccine developmentH influenzaePneumococcal serotypesHaemophilus influenzae protein DSignificant health care burdenAdditional pneumococcal serotypesCorrelates of protectionHealth care burdenRecurrent otitis mediaEffectiveness of vaccinesTympanostomy tube insertionProtein-based vaccinesCandidate vaccine antigensOM pathogensOM visitsPCV effectivenessPneumococcal vaccineRespiratory virusesVaccine protectionTube insertionMoraxella catarrhalisCare burden
2015
Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US
Alfaro-Murillo JA, Townsend JP, Galvani AP. Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US. Vaccine 2015, 34: 225-229. PMID: 26631416, DOI: 10.1016/j.vaccine.2015.11.039.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolCytomegalovirus InfectionsCytomegalovirus VaccinesDisease Transmission, InfectiousFemaleHumansImmunization ScheduleInfantInfant, NewbornInfectious Disease Transmission, VerticalMaleMass ScreeningMiddle AgedUnited StatesYoung AdultConceptsVaccine waningVaccine efficacyOptimal ageCMV vaccine candidatesLongitudinal clinical evaluationChild-bearing yearsYears of ageTransmission dynamicsCMV prevalenceCMV vaccinationCytomegalovirus ScreeningSeronegative femalesCongenital infectionCytomegalovirus infectionVaccine protectionSuch vaccinationClinical evaluationClinical trialsHearing lossVaccine candidatesVaccinationDemographic dataCongenital diseaseCognitive deficitsIndirect protection
2013
Novel Biopanning Strategy To Identify Epitopes Associated with Vaccine Protection
Bachler B, Humbert M, Palikuqi B, Siddappa N, Lakhashe S, Rasmussen R, Ruprecht R. Novel Biopanning Strategy To Identify Epitopes Associated with Vaccine Protection. Journal Of Virology 2013, 87: 4403-4416. PMID: 23388727, PMCID: PMC3624354, DOI: 10.1128/jvi.02888-12.Peer-Reviewed Original ResearchConceptsSimian-human immunodeficiency virusRhesus macaquesHIV-1Vaccinated rhesus macaquesHIV-1 vaccineVaccine protectionScreen plasma samplesHIV-1 TatMucosal challengeImmune correlatesImmunodeficiency virusNT AbsAb responsesVaccine recipientsAb titersAb epitopesVaccine failurePlasma samplesMulticomponent vaccineProtective effectIn vivoDetection AbVaccineFunctional assaysDisease models
2008
Vaccine Protection by Live, Attenuated Simian Immunodeficiency Virus in the Absence of High-Titer Antibody Responses and High-Frequency Cellular Immune Responses Measurable in the Periphery
Mansfield K, Lang S, Gauduin M, Sanford H, Lifson J, Johnson R, Desrosiers R. Vaccine Protection by Live, Attenuated Simian Immunodeficiency Virus in the Absence of High-Titer Antibody Responses and High-Frequency Cellular Immune Responses Measurable in the Periphery. Journal Of Virology 2008, 82: 4135-4148. PMID: 18272584, PMCID: PMC2292994, DOI: 10.1128/jvi.00015-08.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, ViralInterferon-gammaIntestinal MucosaLymphoid TissueMacaca mulattaNeutralization TestsRetroviridae ProteinsRNA, ViralSAIDS VaccinesSequence DeletionSimian Acquired Immunodeficiency SyndromeSimian immunodeficiency virusT-LymphocytesVaccines, AttenuatedViral Envelope ProteinsViral LoadViremiaConceptsAnti-SIV antibody responsesSimian immunodeficiency virusAntibody responseImmune responseVaccine protectionImmunodeficiency virusCopies/Gamma interferon enzyme-linked immunospotVaccine/challenge experimentsAttenuated simian immunodeficiency virusGut-associated lymphoid tissueHigh-titer antibody responsesAnti-SIV immune responsesEnzyme-linked immunospotMacrophage marker CD68Cellular immune responsesHumoral immune responseViral load measurementsWeeks of infectionNeutralization-resistant strainDouble-labeling experimentsVaccinated monkeysViral loadPeripheral bloodLymphoid tissue
1999
Experimental approaches to the development of a recombinant hookworm vaccine
Hotez P, Ghosh K, Huwdon J, Narasimhan S, Jones B, Shuhua X, Sen L, Bin Z, Haechou X, Hainan R, Heng W, Koski R. Experimental approaches to the development of a recombinant hookworm vaccine. Immunological Reviews 1999, 171: 163-171. PMID: 10582170, DOI: 10.1111/j.1600-065x.1999.tb01347.x.Peer-Reviewed Original ResearchConceptsHookworm infectionHeavy hookworm infectionMajor parasitic causeHookworm antigensSerologic correlatesVaccine protectionChallenge infectionHookworm burdenHookworm vaccineParasitic causesEndemic areasHuman infectionsInfectionLaboratory animalsVaccineAlum precipitateMorbidityRecombinant polypeptidesHookwormAntigenDiseaseMiceImmunityAntibodies
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply